Rare Disease, Rapid Progress: FDA’s HAE Approvals in 2025 Signal Changing Course

HCP Live December 3, 2025
Daniel Soteres, MD, PhD, Raffi Tachdjian, MD, MPH, Michael Manning, MD Fact checked by: Chelsie Derman, Patrick Campbell

Key Takeaways

• The FDA approved three new HAE treatments in 2025, expanding options for personalized patient care and management strategies.
• HAE is a rare genetic disorder causing unpredictable swelling, with significant diagnostic challenges and impacts on patients’ lives,...

Today's Sponsors

Today's Sponsor